Skip to main content
Erschienen in: Journal of Neural Transmission 4/2012

01.04.2012 | Basic Neurosciences, Genetics and Immunology - Original Article

Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase

verfasst von: Keiko Inaba-Hasegawa, Yukihiro Akao, Wakako Maruyama, Makoto Naoi

Erschienen in: Journal of Neural Transmission | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Rasagiline and (−)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders. In this paper, the role of MAO in the up-regulation of neuroprotective Bcl-2 gene by these inhibitors was studied using type A MAO (MAO-A) expressing wild SH-SY5Y cells and the transfection-enforced MAO-B overexpressed cells. Rasagiline and (−)deprenyl, and also befloxatone, a reversible MAO-A inhibitor, increased Bcl-2 mRNA and protein in SH-SY5Y cells. Silencing MAO-A expression with short interfering (si) RNA suppressed Bcl-2 induction by rasagiline, but not by (−)deprenyl. MAO-B overexpression inhibited Bcl-2 induction by rasagiline and befloxatone, but did not affect that by (−)deprenyl, suggesting the different mechanisms behind Bcl-2 gene induction by these MAO-B inhibitors. The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors.
Literatur
Zurück zum Zitat Abu-Raya S, Tabakman R, Blaugrund E, Trembovier V, Lazaroyici P (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434:109–116PubMedCrossRef Abu-Raya S, Tabakman R, Blaugrund E, Trembovier V, Lazaroyici P (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434:109–116PubMedCrossRef
Zurück zum Zitat Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (2002) An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline) enhances expression of antiapoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326:105–108PubMedCrossRef Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (2002) An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline) enhances expression of antiapoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326:105–108PubMedCrossRef
Zurück zum Zitat Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases; a kinetic and crystallographic analysis. J Med Chem 48:8148–8154PubMedCrossRef Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases; a kinetic and crystallographic analysis. J Med Chem 48:8148–8154PubMedCrossRef
Zurück zum Zitat Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of l-deprenyl to madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64:113–127PubMedCrossRef Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of l-deprenyl to madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64:113–127PubMedCrossRef
Zurück zum Zitat Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72:248–254PubMedCrossRef Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72:248–254PubMedCrossRef
Zurück zum Zitat Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH, Chien CS, Ho LL-T, Lee CH, Chang YL (2006) Moclobemide upregulated Bcl-2 expression and induce neural stem cell differentiation into serotoninergic neurons via extracellular-regulated kinase pathway. Br J Pharmacol 148:587–598PubMedCrossRef Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH, Chien CS, Ho LL-T, Lee CH, Chang YL (2006) Moclobemide upregulated Bcl-2 expression and induce neural stem cell differentiation into serotoninergic neurons via extracellular-regulated kinase pathway. Br J Pharmacol 148:587–598PubMedCrossRef
Zurück zum Zitat Dagda RK, Zhu J, Chu CT (2009) Mitochondrial kinases in Parkinson’s disease: converging insights from neurotoxin and genetic models. Mitochondrion 9:289–298PubMedCrossRef Dagda RK, Zhu J, Chu CT (2009) Mitochondrial kinases in Parkinson’s disease: converging insights from neurotoxin and genetic models. Mitochondrion 9:289–298PubMedCrossRef
Zurück zum Zitat De Zutter GS, Davis RJ (2001) Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 98:6168–6173PubMedCrossRef De Zutter GS, Davis RJ (2001) Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 98:6168–6173PubMedCrossRef
Zurück zum Zitat Desagher S, Osen-Sand A, Nichols A, Eskes R, Monteaauit S, Lauper S, Maundrell K, Antonsson B, Martinou J-C (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901PubMedCrossRef Desagher S, Osen-Sand A, Nichols A, Eskes R, Monteaauit S, Lauper S, Maundrell K, Antonsson B, Martinou J-C (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901PubMedCrossRef
Zurück zum Zitat Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, ReFacy HE, Carlson EC (2006) Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 7:1513–1529PubMed Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, ReFacy HE, Carlson EC (2006) Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 7:1513–1529PubMed
Zurück zum Zitat Ekblom J, Oreland L, Chen K, Shih JC (1998) Is there a “non-MAO” macromolecular target for L-deprenyl?: Studies on MAOB mutant mice. Life Sci 63:PL161–PL186CrossRef Ekblom J, Oreland L, Chen K, Shih JC (1998) Is there a “non-MAO” macromolecular target for L-deprenyl?: Studies on MAOB mutant mice. Life Sci 63:PL161–PL186CrossRef
Zurück zum Zitat Finberg JP, Lamendorf I, Weinstock M, Schwartz M, Youdim MBH (1999) Pharmacology of rasagiline [N-propargyl-1R-aminoindan]. Adv Neurol 80:495–499PubMed Finberg JP, Lamendorf I, Weinstock M, Schwartz M, Youdim MBH (1999) Pharmacology of rasagiline [N-propargyl-1R-aminoindan]. Adv Neurol 80:495–499PubMed
Zurück zum Zitat Fitzgerald JC, Ufer C, Billett EE (2007) A link between monoamine oxidase-A and apoptosis in serum derived human SH-SY5Y cells. J Neural Transm 114:807–810PubMedCrossRef Fitzgerald JC, Ufer C, Billett EE (2007) A link between monoamine oxidase-A and apoptosis in serum derived human SH-SY5Y cells. J Neural Transm 114:807–810PubMedCrossRef
Zurück zum Zitat Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469PubMedCrossRef Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469PubMedCrossRef
Zurück zum Zitat Hubalek F, Binda C, Ki M, Herzig Y, Sterling J, Youdim MBH, Mattevi A, Edmondson DE (2004) Inactivation of purified human recombinant monoamine oxidase A and B by rasagiline and its analogues. J Med Chem 47:1760–1768PubMedCrossRef Hubalek F, Binda C, Ki M, Herzig Y, Sterling J, Youdim MBH, Mattevi A, Edmondson DE (2004) Inactivation of purified human recombinant monoamine oxidase A and B by rasagiline and its analogues. J Med Chem 47:1760–1768PubMedCrossRef
Zurück zum Zitat Hynson RMG, Kelly SM, Price NC, Ramsay RR (2004) Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophy Acta 1472:60–66 Hynson RMG, Kelly SM, Price NC, Ramsay RR (2004) Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophy Acta 1472:60–66
Zurück zum Zitat Kornhuber J, Konradi C, Mack-Burkhardt F, Riederer P, Heinsen H, Beckmann H (1989) Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 499:81–86PubMedCrossRef Kornhuber J, Konradi C, Mack-Burkhardt F, Riederer P, Heinsen H, Beckmann H (1989) Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 499:81–86PubMedCrossRef
Zurück zum Zitat Kraml M (1965) A rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14:1684–1686CrossRef Kraml M (1965) A rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14:1684–1686CrossRef
Zurück zum Zitat Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MBH, Riederer P, Gerlach M, Oertel WH (2001) Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 108:985–1009PubMedCrossRef Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MBH, Riederer P, Gerlach M, Oertel WH (2001) Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 108:985–1009PubMedCrossRef
Zurück zum Zitat Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szöko E (2004) Pharmacological aspects of (−)-deprenyl. Curr Med Chem 11:2017–2031PubMed Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szöko E (2004) Pharmacological aspects of (−)-deprenyl. Curr Med Chem 11:2017–2031PubMed
Zurück zum Zitat Malorni W, Giammarioli P, Pietrangeli E, Agostinelli E, Ciaccio A, Grassili E, Mondove B (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 426:155–159PubMedCrossRef Malorni W, Giammarioli P, Pietrangeli E, Agostinelli E, Ciaccio A, Grassili E, Mondove B (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 426:155–159PubMedCrossRef
Zurück zum Zitat Maragos WF, Tillman PA, Chesnut MD, Jakel RJ (1999) Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res 834:168–172PubMedCrossRef Maragos WF, Tillman PA, Chesnut MD, Jakel RJ (1999) Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res 834:168–172PubMedCrossRef
Zurück zum Zitat Maruyama W, Takahashi T, Naoi M (1998) (−)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70:2510–2515PubMedCrossRef Maruyama W, Takahashi T, Naoi M (1998) (−)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70:2510–2515PubMedCrossRef
Zurück zum Zitat Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727–735PubMedCrossRef Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727–735PubMedCrossRef
Zurück zum Zitat Maruyama W, Takahashi T, Youdim M, Naoi M (2002) The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109:467–481PubMedCrossRef Maruyama W, Takahashi T, Youdim M, Naoi M (2002) The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109:467–481PubMedCrossRef
Zurück zum Zitat Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44:393–400PubMedCrossRef Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44:393–400PubMedCrossRef
Zurück zum Zitat Naoi M, Maruyama W (2009) Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease. Expert Rev Neurother 9:1233–1250PubMedCrossRef Naoi M, Maruyama W (2009) Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease. Expert Rev Neurother 9:1233–1250PubMedCrossRef
Zurück zum Zitat Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharmaceu Designs 16:2799–2817 Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharmaceu Designs 16:2799–2817
Zurück zum Zitat Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka Y (2006) Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm (71):67–77 Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka Y (2006) Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm (71):67–77
Zurück zum Zitat Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Eng J Med 361:1268–1278CrossRef Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Eng J Med 361:1268–1278CrossRef
Zurück zum Zitat Ou X-M, Chen K, Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103:10923–10928PubMedCrossRef Ou X-M, Chen K, Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103:10923–10928PubMedCrossRef
Zurück zum Zitat Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R, Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200–1206PubMedCrossRef Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R, Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200–1206PubMedCrossRef
Zurück zum Zitat Parkinson Study Group (1993) Effects of tocopherol and deprenyl on progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183CrossRef Parkinson Study Group (1993) Effects of tocopherol and deprenyl on progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183CrossRef
Zurück zum Zitat Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033–2043PubMed Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033–2043PubMed
Zurück zum Zitat Shacka JJ, Roth KA (2005) Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr Drug Targets CNS Neurol Disord 4:24–39CrossRef Shacka JJ, Roth KA (2005) Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr Drug Targets CNS Neurol Disord 4:24–39CrossRef
Zurück zum Zitat Tatton WG, Ju WYL, Holland D, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572–1575PubMedCrossRef Tatton WG, Ju WYL, Holland D, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572–1575PubMedCrossRef
Zurück zum Zitat Tazik S, Johnson S, Lu D, Johnson C, Youdim MBH, Stockmeler CA, Ou X-M (2009) Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotoxic Res 15:284–290CrossRef Tazik S, Johnson S, Lu D, Johnson C, Youdim MBH, Stockmeler CA, Ou X-M (2009) Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotoxic Res 15:284–290CrossRef
Zurück zum Zitat Yi H, Akao Y, Maruyama W, Chen K, Shih JC, Naoi M (2006a) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96:541–549PubMedCrossRef Yi H, Akao Y, Maruyama W, Chen K, Shih JC, Naoi M (2006a) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96:541–549PubMedCrossRef
Zurück zum Zitat Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MB, Naoi M (2006b) N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113:21–32PubMedCrossRef Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MB, Naoi M (2006b) N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113:21–32PubMedCrossRef
Zurück zum Zitat Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309PubMedCrossRef Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309PubMedCrossRef
Zurück zum Zitat Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MBH, Le W (2008) Comparison of neuroprotective and neurorestorative capacities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopamine degeneration. J Neurochem 105:1970–1978PubMedCrossRef Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MBH, Le W (2008) Comparison of neuroprotective and neurorestorative capacities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopamine degeneration. J Neurochem 105:1970–1978PubMedCrossRef
Metadaten
Titel
Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase
verfasst von
Keiko Inaba-Hasegawa
Yukihiro Akao
Wakako Maruyama
Makoto Naoi
Publikationsdatum
01.04.2012
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 4/2012
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-011-0730-6

Weitere Artikel der Ausgabe 4/2012

Journal of Neural Transmission 4/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.